Clinical Trial

A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

Study acronym: CAPTIVATE
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this Phase 3 study is to demonstrate the efficacy of claseprubart (DNTH103) as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).
Protocol Amendment History 4 changes
notable Trial sites expanded: 168 -> 180 locations 2026-07-14
notable Trial sites expanded: 158 -> 167 locations 2026-05-14
notable Enrollment reduced: 480 -> 256 participants 2026-04-22
minor Trial arms changed: 5 -> 4 2026-04-22
Trial Details
NCT Number NCT06858579
Lead Sponsor Dianthus Therapeutics
Conditions Chronic Inflammatory Demyelinating Polyneuropathy
Enrollment 256 participants
Start Date 2025-02-10
Primary Completion 2028-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-13